0001104659-18-022155.txt : 20180403 0001104659-18-022155.hdr.sgml : 20180403 20180403160816 ACCESSION NUMBER: 0001104659-18-022155 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180330 FILED AS OF DATE: 20180403 DATE AS OF CHANGE: 20180403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schranz Jennifer CENTRAL INDEX KEY: 0001735382 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 18733411 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2018-03-30 0 0001641640 Nabriva Therapeutics plc NBRV 0001735382 Schranz Jennifer 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 Chief Medical Officer Stock Option 2018-03-30 4 A 0 150000 0.00 A 2028-03-30 Ordinary Shares 150000 150000 D The exercise price is $5.03 per share. This option was granted on March 30, 2018. Vesting will begin on March 30, 2018 and end on March 31, 2022. Twenty-five percent (25%) of the option will vest on March 31, 2019, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Robert Crotty, by power of attorney 2017-04-03